Last reviewed · How we verify
Juvidex
Juvidex is a Small molecule drug developed by Renovo. It is currently in Phase 2 development. Also known as: Mannose-6-phosphate, M6P, RN1004.
Juvidex is a small molecule with the chemical name Mannose-6-phosphate. It is being studied in clinical trials for its potential to accelerate the healing of split thickness skin graft donor sites and other wound-related conditions.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Juvidex |
|---|---|
| Also known as | Mannose-6-phosphate, M6P, RN1004 |
| Sponsor | Renovo |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Investigation Into the Safety and Scar-improvement Efficacy of Intradermal Juvidex Dosed Once or Three Times (PHASE2)
- Investigation Into the Safety of Intradermal Juvidex (M6P) Administered to Wounds of Healthy Subjects (PHASE1)
- Pharmacogenomic Analysis of Samples From Subjects in Study RN1004-0082
- Juvidex (Mannose-6-Phosphate) in Accelerating the Healing of Split Thickness Skin Graft Donor Sites (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Juvidex CI brief — competitive landscape report
- Juvidex updates RSS · CI watch RSS
- Renovo portfolio CI
Frequently asked questions about Juvidex
What is Juvidex?
Who makes Juvidex?
Is Juvidex also known as anything else?
What development phase is Juvidex in?
Related
- Manufacturer: Renovo — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Mannose-6-phosphate, M6P, RN1004
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing